Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment

Cutis

Volumn 92, Issue 3, 2013, Pages 140-147

  Famenini, Shannon ^a   Wu, Jashin J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOTHERAPY; PSORIASIS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886010128     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. National Institutes of Health. Psoriasis fact sheet. http://report.nih.gov/nihfactsheets/Pdfs/Psoriasis%28NIAMS%29.pdf. Updated October 2010. Accessed August 23, 2013.
2. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:274-285.
3. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
4. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
5. Papp S, Tyring M, Lahfa J. A global phase 3 study of etan-ercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
6. Kamili QU, Miner A, Hapa A, et al. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. J Drugs Dermatol. 2011;10:539-544.
7. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374.
8. Menter A, Feldman SR, Weinstein GD, et al. A random-ized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis [published online ahead of print September 6, 2006]. J Am Acad Dermatol. 2007;56:31.e1-31.e15.
9. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. a randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40-49.
10. Ardigò M, Giuliani A, de Felice C, et al. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. J Drugs Dermatol. 2008;7:935-939.
11. Papp K, Ho V, Teixeira HD, et al. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study [published online ahead of print October 25, 2011]. J Eur Acad Dermatol Venereol. 2012;26:1007-1113.
12. Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37:299-310.
13. Gordon KB, Blum RR, Papp KA, et al. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum. 2007;13:6-11.
14. Gordon KB, Langley RG, Leonardi C, et al. Clinical re-sponse to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study [published online ahead of print August 10, 2006]. J Am Acad Dermatol. 2006;55:598-606.
15. Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial [published online ahead of print December 20, 2010]. Arch Dermatol. 2011;147:429-436.
16. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
17. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) [published online ahead of print November 28, 2007]. Br J Dermatol. 2008;158:558-566.
18. van der Heijde D, Klareskog L, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:3928-3939.
19. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial [published online ahead of print July 16, 2008]. Lancet. 2008;372:375-382.
20. Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495-501.
21. Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis [published online ahead of print July 28, 2008]. Br J Dermatol. 2008;159:460-463.
22. Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial [published online ahead of print April 10, 2008]. Br J Dermatol. 2008;158:1345-1349.
23. Smith ECA, Riddle C, Menter MA, et al. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008;47:514-518.
24. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol. 2009;8:546-559.
25. De Simone C, D'Agostino M, Capizzi R, et al. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol. 2011;21:568-572.
26. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept [pub-lished online ahead of print November 25, 2008]. Br J Dermatol. 2009;160:186-189.
27. Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept [published online ahead of print August 10, 2011]. J Dermatolog Treat. 2012;23:261-267.
28. Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. 2011;164:1383-1386.
29. Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis [published online ahead of print May 17, 2010]. Ann Dermatol. 2010;22:138-142.
30. Kircik LH. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10:878-882.
31. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis [published online ahead of print November 17, 2006]. J Am Acad Dermatol. 2007;56:598-603.
32. Gottlieb AB, Kircik L, Eisen D, et al. ?Use of etaner-etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatol Treat. 2006;17:343-352.
33. Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol. 2004;3:270-272.
34. Conley J, Nanton J, Dhawan S, et al. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-a case series. J Dermatol Treat. 2006;17:86-89.
35. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645-660.
36. D'Angelo S, Cutro M, Lubrano E, et al. Combination therapy with cyclosporine and etanercept in patients with psoriatic arthritis [published online ahead of print August 9, 2009]. Ann Rheum Dis. 2010;69:934-935.
37. Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort [published online ahead of print December 19, 2008]. J Eur Acad Dermatol Venereol. 2009;23:277-282.
38. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study [published online ahead of print May 26, 2004]. Arthritis Res Ther. 2004;6:R326-R334.
39. El-Hag K, Dercken HG, Prenzel R, et al. Drug-induced alveolitis associated with infliximab/azathioprine therapy. Pneumologie. 2008;62:204-208.
40. Farreli RJ, Alsahli M, Falchuk KR, et al. Human anti-chimeric antibody levels correlate with a lack of response and infusion reactions following infliximab therapy. Gastroenterology. 2001;120(suppl 1):A69.
41. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
42. Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis. J Drugs Dermatol. 2011;10:366-371.
43. Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study [published online ahead of print April 2, 2010]. Br J Dermatol. 2010;16:402-411.